2021 Pediatric Grand Rounds | Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy

Duarte, CA US
June 10, 2021

Neuroblastoma is one of the most common types of pediatric solid tumors and yet targeted immunotherapy of this disease is very limited. Pediatric oncologists need to stay abreast on advances in neuroblastoma management in order to apply the current state of the field to pediatric malignancies where appropriate.  It is therefore, imperative that they hear from a leading expert in the field, to understand how the results of molecular evaluations alter management. Genomic advances have altered the landscape of neuroblastoma management.  As more data is acquired, risk stratification and therapy continues to evolve.

Target Audience

City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.

Learning Objectives

  • Integrate advances in neuroblastoma management into current practices.
  • Discuss applicability of these advances to management of other pediatric malignancies.
  • Identify risk stratification by molecular evaluations in pediatric neuroblastoma.
     

Additional Information

AttachmentSize
PDF icon AB 1195 Bibliography_Neuroblastoma163.35 KB
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2021 Pediatric Grand Rounds | Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
06/10/2021
Activity expires: 
06/11/2021
Event starts: 
06/10/2021 - 12:00pm
Event ends: 
06/10/2021 - 1:00pm
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Araz Marachelian, MD, MS  Assistant Professor of Pediatrics, University of Southern California; Medical Director, NANT Operation’s Office; Children’s Hospital Los Angeles

Dr. Marachelian has indicated that is receives Grant/Research Support from Pfizer and United Therapeutics; Consultant for United Therapeutics and YmAbs Therapeutics. 

Dr. Marachelian will be discussing the off-label or investigational use of isotretinoin, cyclophosphamide, topotecan, dinutuximab, dinutiximab-Beta, accutane, cisplatin, metaiodobenzylguanidine (MIBG), irinotecan-temozolomide, temsirolimus, vincristine, irinotecan, omburtamab, alisertib, crizotinib, lorlatinib, and vorinostat.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

 AMA PRA Category 1™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2021 Pediatric Grand Rounds | Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.